Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in Polycythemia Vera
NCT01120821Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2002
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in polycythemia vera (PV), sponsored by Weill Cornell Medicine. Primary endpoints: Stabilization of hematocrit at 1 year and Platelet count maintenance a therapeutic range at 1 year. Started Aug 2002; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT01120821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120821.